Neuroprotective effects of D3 dopamine receptor agonists

Parkinsonism and Related Disorders

Volumn 7, Issue 3, 2001, Pages 213-223

  Carvey, P M ^a   McGuire, S O ^a   Ling, Z D ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bcl 2; D3 receptor; Dopamine agonists; Dopamine antagonists; Neuroprotection; Parkinson's disease; Tissue culture; Trophic factors

Indexed keywords

2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; ANTIPARKINSON AGENT; BROMOCRIPTINE; CLOZAPINE; DOMPERIDONE; DOPAMINE 3 RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HALOPERIDOL; LEVODOPA; NEUROTROPHIC FACTOR; OLANZAPINE; PERGOLIDE; PRAMIPEXOLE; PROTEIN BCL 2; RACLOPRIDE; ROPINIROLE; TUMOR NECROSIS FACTOR ALPHA; U 95666; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; CELL CULTURE; CONFERENCE PAPER; DOPAMINERGIC SYSTEM; DOSE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0035032450     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(00)00061-4     Document Type: Conference Paper

References (100)

1. Parkinson's disease: pathophysiology
2. Are dopaminergic neurons selectively vulnerable to Parkinson's disease?
3. First trimester development of the human nigrostriatal dopamine system
4. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine lesioned mouse brain
5. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis
6. Pramipexole - a new dopamine agonist for the treatment of Parkinson's disease
7. A comparative review of new antipsychotics
8. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease
9. Monoamine oxidase molecular activity in platelets of parkinsonian and demented patients
10. Structure/function in neuroprotection and apoptosis
11. Free radical activity of melanins and related substances: biochemical and pathobiochemical aspects
12. Neural apoptosis
13. Ceramide induces apoptosis in cultured mesencephalic neurons
14. Programmed cell death: does it play a role in Parkinson's disease?
15. Programmed cell death and Parkinson's disease
16. Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture
17. Lisuride prevents learning and memory impairment and attenuates the increase in extracellular dopamine induced by transient global cerebral ischemia in rats
18. Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism
19. Alterations in striatal neurotrophic activity induced by dopaminergic
20. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures
21. Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neurons
22. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole
23. Apoptosis and Bcl-2 oncoprotein expression in the human fetal central nervous system
24. Free-radical toxicity and antioxidant medication in Parkinson's disease
25. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells
26. Therapeutic potential of nerve growth factors in Parkinson's disease
27. Development and survival of neurons in dissociated fetal mesencephalic serum-free cell cultures: I. Effects of cell density and of an adult mammalian striatal-derived neuronotrophic factor (SDNF)
28. Effect of pergolide on endogenous and exogenous L-Dopa metabolism in rat striatum: a microdialysis study
29. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats
30. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction
31. Lazaroid treatment prevents death of cultured rat embryonic mesencephalic neurons following glutathione depletion
32. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons
33. Autoradiographic localization of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907
34. Bcl-2 influences axonal growth rate in embryonic sensory neurons
35. Does oxidative stress participate in nerve cell death in Parkinson's disease?
36. Iron metabolism and Parkinson's disease
37. Neuronal vulnerability in Parkinson's disease
38. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?
39. Biochemical pathophysiology of Parkinson's disease
40. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease
41. Nuclear translociation of NF-kB is increased in dopaminergic neurons of patients with Parkinson Disease
42. FceRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-α in glial cells
43. Oxidative stress in Parkinson's disease and other neurodegenerative disorders
44. Oxidative mechanisms in nigral cell death in Parkinson's disease
45. Oxidative stress and the pathogenesis of Parkinson's disease
46. Understanding cell death in Parkinson's disease
47. Expression of bcl-2 inhibits necrotic neural cell death
48. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells
49. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum
50. Reactive oxygen species and the neurodegenerative disorders
51. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes
52. Astrocytes promote or impair the survival and function of embryonic ventral mesencephalon co-grafts: effects of astrocyte age and expression of recombinant brain-derived neurotrophic factor
53. The D3 dopamine receptor: neurobiology and potential clinical relevance
54. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist
55. Pramipexole reduces levodopa-induced dopamine neuron toxicity in tissue culture
56. Comparison of the neurotoxicity of dihydroxyphenylalanine (dopa) stereoisomers in cultured dopamine neurons
57. Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures
58. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures
59. Iron, free radicals and oxidative injury
60. TNF α reduces tyrosine hydroxylase immunoreactivity in mesencephalic cultures
61. TNF α-induced toxicity in mesencephalic dopamine neurons is dose and time dependent
62. Levodopa toxicity and apoptosis
63. Mitochondrial dysfunction in Parkinson's disease
64. Determinants of neuronal vulnerability in neurodegenerative diseases
65. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice
66. Scavenging effects of dopamine agonists on nitric oxide radicals
67. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity
68. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro
69. An introduction to the free radical hypothesis in Parkinson's disease
70. A radical hypothesis for neurodegeneration
71. Attempts to obtain neuroprotection in Parkinson's disease
72. Dopamine agonists and neuroprotection in Parkinson's disease
73. Current status of selegiline as a neuroprotective agent in Parkinson's disease
74. Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia
75. Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum
76. Oxidative stress and Parkinson's disease
77. Functional potencies of new antiparkinsonian drugs at recombinant human D1, D2, and D3 receptors
78. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists
79. In vitro studies on central dopaminergic neurons' development
80. Experimental developments in movement disorders: update on proposed free radical mechanisms
81. Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease
82. NGF, BDNF.and NT-5, but not NT-3 protect against MPP+ toxicity and oxidative stress in neonatal animals
83. Specification and survival of dopaminergic neurons in the mammalian midbrain
84. Release of endogenous dopamine in cultured mesencephalic neurons: influence of dopaminergic agonists and glucocorticoid antagonists
85. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease
86. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats
87. Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux
88. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
89. Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease
90. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons
91. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors
92. PTX-sensitive regulation of neurite outgrowth by the dopamine D3 receptor
93. Inhibitory effects of bromocriptine on phospholipid peroxidation induced by DOPA and iron
94. Mitochondria in neurodegenerative apoptosis: an opportunity for therapy?
95. Pramipexole has antioxidant properties and inhibits lipid peroxidation
96. Pharmacological approaches to counter the toxicity of Dopa
97. A Bcl-2 antisense oligonucleotide increases alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) toxicity in cortical cultures
98. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2
99. Antioxidant properties of bromocriptine, a dopamine agonist